Who is sponsoring NCT05059002?

NCT05059002 is sponsored by EpiWatch, Inc..

What drugs are being tested in NCT05059002?

Interventions in NCT05059002: Physiological signal monitoring and seizure detection.

What condition does NCT05059002 study?

NCT05059002 studies Epilepsy, Tonic-Clonic.

Is NCT05059002 still recruiting?

NCT05059002 is currently completed. Last updated 4 February 2025.

Last reviewed 2025-02-04 · How we verify

NCT05059002

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EpiWatch: Evaluation of a Non-EEG Physiological Signal Based Seizure Monitoring System

Completed NA Last updated 4 February 2025

What this trial tests

NA trial testing Physiological signal monitoring and seizure detection in Epilepsy, Tonic-Clonic in 242 participants. Completed in 31 October 2023.

Timeline

20 September 2021

Primary endpoint
31 October 2023

31 October 2023

Quick facts

Lead sponsor	EpiWatch, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	242
Start date	20 September 2021
Primary completion	31 October 2023
Estimated completion	31 October 2023
Sites	1 location across United States

Drugs / interventions tested

Physiological signal monitoring and seizure detection

Conditions studied

Epilepsy, Tonic-Clonic — all drugs for Epilepsy, Tonic-Clonic →

Sponsor

EpiWatch, Inc.

Who can join

5 and older, any sex, with Epilepsy, Tonic-Clonic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To demonstrate the safety and effectiveness of the EpiWatch device in identifying tonic-clonic (TC) seizures, notifying a third-party of TC seizure occurrence, and collecting non-EEG physiological data for subsequent review during patient hospitalization in an epilepsy monitoring unit (EMU).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Epilepsy, Tonic-Clonic

Currently open trials in the same condition.

NCT06967012 — A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05059002 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by EpiWatch, Inc.
Last refreshed: 4 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05059002.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing